== Inhibitors ==

#Jasplakinolide (molecular probes, J-7473): 4 uM 15 min, or 2 M 15 min, 25nM 4h or 50nM 2h give good morphorlogy
#ML7: blocking MLCK, 5mM stock, 30 M working concentration.


=== For HUVECs ===
*Cyto D: 0.2 uM, 1 hr 
*Taxol: 0.5 uM, 2 hr
*Noco: 1 uM, 1 hr


{|border="1"
|-
|Targeting Molecule||Inhibitors||Concentration (uM)||Duration (min)
|-
|Src||PP2||10 ||1 hr
|-
|Src||PP1||10||1 hr
|-
|Src||SU6656||10||1 hr
|-
|RTK||Saurumine||50||1 hr
|-
|MAPK||PD98…||10||1 hr
|-
|FAK||AG82…||20||1 hr 
|-
|FAK||NVP-TAE226||1 uM||4 hr? 
|-
|FLK-1 (VEGFR-2)||SU4819||5 uM||1 hr 
|-
|MicroTubules||Colchicine||1||1 hr
|-
|MicroTubules||Paclitaxel (taxol; stablizing)||1 uM||2 hr
|-
|Actin filaments||Cyto D||1||1 hr
|-
|Actin filaments||Latrunculin B (sequester G-monomer)||0.5 uM||1 hr
|-
|Actin filaments||Jasplakinolite (stabilizing)||100 nM||1 hr
|-
|PI3K||Wortmannin||1||1 hr
|-
|Myosin ATPase||BDM||10 mM||1 hr
|-
|Myosin II||Blebbistatin||10 uM||1 hr
|-
|ROCK||Y27…||10||1 hr
|-
|MLCK||ML-7; ML-9||10 or 5; 7.5||1 hr
|-
|PI3K||LY 29…||50||1 hr
|-
|apoptosis||Pancaspase inhibitor zVAD-fmk||10 uM||
|-
|de novo protein synthesis||cycloheximide||25 ug/ml||
|-|MEK||UO126 (promega)||25||''-''
|}



{|border="1"
|-
|Targeting Molecule||Stimuli||Concentration (uM)||Duration (min)
|-
|RhoA||LPA||200 ng/ml||30 min
|-
|Rac||PDGF||25 ng/ml||30 min
|-
|Cdc42||bradykinin||100 nM||3 min
|-
|integrins a5b1, avb3, avb5||Fibronectin||10 ug/ml||1 hr
|-
|integrins avb3||Fibronogen, Vitronectin||||
|-
|integrins a1b1, a2b1||collagen||||
|-
|integrins a1b1, a2b1, a3b1 and a6b1||laminin||||
|}


serum starved for 16 hr. Cells were either treated with LPA (200 ng/ml−1) for 30 min (Sigma, Poole, UK), PDGF (25 ng/ml−1) for 30 min (TCS Biologicals, Botolph Claydon, UK), or bradykinin (100 nM) for 3 min (Sigma) or were plated on fibronectin (BD Biosciences) (10 μg/ml) for 1 hr.